Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum

Corrigendum to Targeting apoptotic pathways for cancer therapy

Xiaobing Tian et al. J Clin Invest. .
No abstract available

PubMed Disclaimer

Erratum for

  • Targeting apoptotic pathways for cancer therapy.
    Tian X, Srinivasan PR, Tajiknia V, Sanchez Sevilla Uruchurtu AF, Seyhan AA, Carneiro BA, De La Cruz A, Pinho-Schwermann M, George A, Zhao S, Strandberg J, Di Cristofano F, Zhang S, Zhou L, Raufi AG, Navaraj A, Zhang Y, Verovkina N, Ghandali M, Ryspayeva D, El-Deiry WS. Tian X, et al. J Clin Invest. 2024 Jul 15;134(14):e179570. doi: 10.1172/JCI179570. J Clin Invest. 2024. PMID: 39007268 Free PMC article. Review.

References

    1. Gieffers C, et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcγ receptors. Mol Cancer Ther. 2013;12(12):2735–2747. doi: 10.1158/1535-7163.MCT-13-0323. - DOI - PubMed
    1. Phillips DC, et al. Hexavalent TRAIL fusion protein eftozanermin alfa optimally clusters apoptosis-inducing TRAIL receptors to induce on-target antitumor activity in solid tumors. Cancer Res. 2021;81(12):3402–3414. doi: 10.1158/0008-5472.CAN-20-2178. - DOI - PubMed
    1. Papadopoulos KP, et al. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol. 2015;75(5):887–895. doi: 10.1007/s00280-015-2712-0. - DOI - PubMed
    1. Fang DD, et al. MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discov. 2021;7(1):90. doi: 10.1038/s41420-021-00465-5. - DOI - PMC - PubMed
    1. Guiley KZ, Shokat KM. A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability. Cancer Discov. 2023;13(1):56–69. doi: 10.1158/2159-8290.CD-22-0381. - DOI - PMC - PubMed

Publication types